Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
277
resultados
Última actualización
11/06/2026 [07:36:00]
Resumen de: EP4755889A1
0001 Disclosed are a novel compound for detecting amyloid-beta, and a method of diagnosing a neurodegenerative disease using the same, wherein a compound represented by Formula 1 or a salt thereof according to the present disclosure may specifically bind to amyloid-beta. Due to its high selectivity, the compound or a salt thereof can detect amyloid-beta in plasma with high sensitivity despite interference in detection caused by the presence of other proteins in plasma, and can be utilized for the diagnosis of a neurodegenerative disease or screening for therapeutic agents for a neurodegenerative disease.
Resumen de: EP4756429A2
0001 The invention relates to novel methods, kits and use of polypeptides for the detection of antibodies against Bovine Herpes Virus Type 1 (BoHV-1) infection in biological samples including milk, pooled milk and bulk milk.
Resumen de: WO2025037271A1
Provided herein are methods and assays for detecting central nervous system (CNS)-derived tau peptides in blood-based samples from subjects, involving the use of a capture antibody that binds to a tau epitope, and a detection antibody that binds to an epitope comprising amino acids residues that span the junction of Exon 4 and Exon 5 of CNS-derived tau.
Resumen de: US20260152566A1
0000 Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
Resumen de: US20260152551A1
0000 The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
Resumen de: US20260153520A1
0000 The present invention relates to a method of detecting one or more tissue-derived aggregated proteins in a biological sample.
Resumen de: US20260151513A1
0000 Compositions and methods for the treatment of leukodystrophy, particularly, H-ABC are disclosed.
Resumen de: WO2024239122A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: US20260153437A1
The invention relates to a multispectral plasmonic sensor for chiral molecular barcoding, employing a pixelated array of nanostructured plasmonic units coupled with a photonic cavity. Each pixel is tuned to resonate at distinct mid-infrared (mid-IR) wavelengths, facilitating simultaneous detection of molecular chiral and vibrational properties. The system generates near-perfect resonant absorption, maximizing electric and magnetic field enhancements. When illuminated with circularly polarized light, the sensor produces a chiral near-field with handedness determined by the polarization direction. The interaction between the sensor and chiral molecules is quantified using dissymmetry factors, forming unique chiral barcodes that encode molecular behavior across multiple wavelengths. The sensor enables surface-enhanced infrared absorption (SEIRA) induced surface-enhanced vibrational circular dichroism (SEVCD) measurements, providing comprehensive chiral and vibrational analysis. This approach creates a unique barcode for every chiral active molecule, supporting advanced applications in chemical analysis and molecular identification.
Resumen de: US20260155261A1
Disclosed are non-pharmaceutical compositions, kits, systems, and methods configured to support immunological fitness and continuous cellular defenses. In certain embodiments, a kit includes a bioavailability-optimized ingestible powder and a bioavailability-optimized ingestible liquid provided together with guidance associating coordinated use of the compositions with activation of one or more biological defense pathways. Additional embodiments include preparedness kits comprising interim vitamin D dosing components and guidance materials suitable for deployment prior to individualized testing. System embodiments may integrate distribution mechanisms, data association components, processing components, and optional environmental sensing to support population-scale risk mitigation. Methods are disclosed for supporting immunological fitness, maintaining biological barriers, and associating measurable biological and environmental metrics with population-level risk assessment and actuarial applications, without requiring pharmaceutical intervention.
Resumen de: WO2026117508A1
The present disclosure provides methods of predicting/diagnosing immunotherapeutic toxicity in a subject using levels of at least one biomarker protein in a biological sample from the subject, wherein the at least one biomarker protein comprises C4orf47, CXCL1, LMNTD2, ERVV-1, PSRC1, SPRED2, KIF22, MRRF, DAAM1, ABO, MAP9, or any combination thereof. Also provided herein are methods of determining therapeutic regimens for patients based on the biomarker levels.
Resumen de: WO2026115269A1
The present invention provides a method for detecting an analyte in a sample, the method comprising steps (i)-(iv). Thus, the present invention provides a method for detecting an analyte in a sample in which only the reporter reagents in the vicinity of the surface of the substrate results in a signal, the signal being a local region having an absence of the optical component. It is the set of local regions of the optical component having an absence of the optical component that are detected.
Resumen de: WO2026116669A1
The present invention relates to a novel microRNA for in vitro early diagnosis of mild cognitive impairment and Alzheimer's dementia, and a convergence diagnostic cartridge and diagnostic device using same. The novel miRNA of SEQ ID NO: 1 obtained by molecular analysis exhibits differences in expression levels in the plasma of a normal group, a mild cognitive impairment patient group, and an Alzheimer's dementia patient group, and has the effect of reducing the expression levels of mild cognitive impairment- and Alzheimer's dementia-related proteins. Therefore, by using a novel miRNA present in plasma as a molecular diagnostic index in a non-invasive manner, the present invention enables not only early diagnosis of Alzheimer's dementia but also screening for mild cognitive impairment and Alzheimer's dementia.
Resumen de: AU2024378628A1
It has proven difficult to automate the detection of neurodegenerative disorders in patients. Thus, detection is currently still performed via visual inspection. Accordingly, embodiments automate the detection of neurodegenerative disorders by deriving sleep biomarker(s) from physiological data, acquired while a subject is sleeping, and applying a classifier to the sleep biomarker(s) to output a risk probability for each neurodegenerative disorder. Embodiments also characterize the neurodegenerative disorder(s) by assigning a risk severity based on the risk probability(ies), output by the classifier.
Resumen de: US20260151494A1
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.
Resumen de: EP4752550A2
0001 Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Resumen de: EP4752856A1
0001 The present invention relates to the field of medical diagnosis, and more particularly to methods for detecting the risk of having mental health-related diseases by means of analyzing morphological changes in specific immune cells of the central nervous system, such as microglia, using convolutional neural network-based artificial intelligence.
Resumen de: EP4752155A1
The present invention relates to genetically encoded cellular iron biosensors, in particular to nucleic acids encoding the same, vectors and cells comprising the nucleic acid(s), in vitro methods for measuring, and optionally monitoring, cellular Fe2+ and/or cellular iron-sulfur cluster (ISC), in vitro screening methods for a compound that affects cellular Fe2+ and/or cellular ISC, and to in vitro methods for identifying a dosage and/or formulation of a compound that affects cellular Fe2+ and/or cellular ISC.
Resumen de: WO2025024817A1
Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.
Resumen de: WO2024229437A2
Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Resumen de: WO2024211475A1
Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
Resumen de: WO2024228056A1
A universal biomarker array enables the diagnosis and localization of earlier-than- now recognizable disease states as well as increasing the accuracy of diagnosing states of disease(s) in general. The universal biomarker array is formed of a range of mathematical parameters computed from digital tissue images showing tissue details at a cellular level. The universal biomarker array includes one or more novel parameter arrays (namely, a spatial entropy array, a bin array, and/or a quartile array) in combination with one or more state-of-the-art parameter arrays (namely, a pattern array, a distance array, and/or a morphology array) and/or in combination with one or more other parameters. An AI/ML system can be used to analyze the universal biomarker array relative to database-based reference data for early diagnosis and localization of disease processes.
Resumen de: WO2024226596A1
Systems, devices, and techniques are configured to leverage acoustic-based microfluidic amplification for the detection of a biological substance, such as misfolded proteins associated with a protein-misfolding disease. In one example, a system (100) includes a housing defining a main channel (104) configured to contain a fluid solution containing a sample including a plurality of proteins and one or more side channels (106) in fluid communication with the main channel, wherein each side channel of the one or more side channels are configured to establish a liquid-gas interface (108) between the fluid solution in the main channel and air contained in the one or more side channels. The systems may also include at least one acoustic generation element configured to generate acoustic waves within the air of the one or more side channels that causes vibration of the liquid-gas interface and mixing of the fluid solution within the main channel.
Resumen de: WO2024223741A1
Disclosed herein is a method for screening a biological fluid sample for an analyte associated with proteinopathy which relies on a signal that is quadratically proportional to a mass difference generated by molecular interactions of a plurality of first molecular recognition elements (10) and a plurality of second molecular recognition elements.
Nº publicación: JP2026517839A 02/06/2026
Solicitante:
大塚製薬株式会社
Resumen de: WO2024231251A1
The present invention relates to antibodies or antigen-binding fragments thereof with binding specificity for interleukin-1 receptor accessory protein (IL1RAP). Furthermore, it relates to a polynucleotide encoding said antibodies, a vector comprising said polynucleotide and a recombinant host cell comprising said polynucleotide or said vector. Further, it relates to a method for producing said antibodies or antigen-binding fragments. Further, it relates to a composition comprising said antibodies or antigen-binding fragments, said polynucleotide, said vector and/or said host cell. Further, it relates to said antibodies or antigen-binding fragments, said polynucleotide, said vector, said host cell and/or said composition for use in medicine and/or for use in the prevention and/or treatment and/or alleviation and/or detection and/or diagnosis of a disease or disorder susceptible to treatment with an inhibitor of IL-1α, IL-1β, IL-33, IL-36α, IL-36β and/or IL- 36γ signaling, optionally wherein the disease or disorder is associated with cells expressing IL1RAP.
BOPI
Sede Electrónica
